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Mandatory Health Insurance Coverage for Cancer Clinical
Trials
Leslie C. Murphy

Code Sections Affected
Health and Safety Code § 1370.6 (new); Insurance Code
§ 10145.4 (new); Welfare and Institutions Code §§ 14087.11,
14132.98, and 14132.99 (new).
SB 37 (Speier); 2001 STAT. Ch. 172.

I. INTRODUCTION

After diagnosing Ms. Judith Harris with advanced-stage breast cancer, her
physician recommended that she consider High Dosage Chemotherapy with
Autologous Bone Marrow Transplant (HDC-ABMT).' This procedure involves
the extraction of the patient's bone marrow, which is frozen and stored.2 The
patient then receives near-lethal doses of chemotherapy. 3 The chemotherapy kills
not only the cancer cells, but also the patient's healthy bone marrow.4 The
previously extracted bone marrow is returned to the patient where it rapidly
duplicates and replaces the bone marrow damaged by the chemotherapy.5 The
cost of HDC-ABMT ranges between $75,000 and $150,000.6
HDC-ABMT is used on patients who have not responded to traditional
chemotherapy.7 Without this treatment, Ms. Harris' chance of survival was grim.8
Ms. Harris' physician referred her to Indiana University Medical Center, where

1. See Harris v. Mut. of Omaha, 992 F.2d 706, 707 (7th Cir. 1993) (describing Ms. Harris' medical
condition).
2. Melody L. Harness, What is "Experimental" Medical Treatment?:A Legislative Definition is Needed,
44 CLEV. ST. L. REV. 67, 74 (1996).
3. Id.
4. Id.
5. Id.
6. See Harris, 992 F.2d at 708 (stating HDC-ABMT costs between $100,000 to $150,000); Adams v.
Blue Cross/Blue Shield, 757 F. Supp. 661, 662 (D. Md. 1991) (stating HDC-ABMT costs approximately
$100,000); Dozsa v. Crum & Forster Ins. Co., 716 F. Supp. 131, 132 (D.N.J. 1989) (stating HDC-ABMT costs
range between $75,000 to $125,000).
7. See Emily Smayda, Current Legal Intervention Regarding "Experimental" Treatments Must be
Changed: An Analysis of High Doses of Chemotherapy with Autologous Bone Marrow Transplantationfor
Breast Cancer Patients, 13 J.L. & HEALTH 257, 257-58 (1998) (describing a young woman with late-stage
breast cancer who endured nine months of chemotherapy and radiation but whose disease still progressed; her
doctor told her without HDC-ABMT she would die).
8. See Harris,992 F.2d at 708 (according to Ms. Harris' doctor, she had "very little" chance of surviving
five years without HDC-ABMT).
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she sought treatment as part of a Phase II clinical trial.9 Ms. Harris requested
authorization for the procedure from her insurance carrier.' ° The authorization
was denied because her insurance policy did not cover experimental treatments."
Ms. Harris' insurance carrier, Mutual of Omaha, defined Phase 1, 11, and III
clinical trials 2 as experimental or investigational. Before any new treatment
becomes acceptable medical practice, clinical trials must indicate that the
treatment is safe and effective for the specific condition. 14 Until a procedure or
drug is considered standard medical practice, insurance companies typically
deem the treatment investigational and experimental."
Whether an insurer should cover experimental medical treatment is a difficult
problem to remedy because determining whether an insurance company covers
treatment is usually a matter of contract law.' 6 Often times, there is a conflict
between the social policy of promoting new effective treatments through 7clinical
trials and insurance carriers' reluctance to pay for an unproven treatment.
This Legislative Note discusses the nature of clinical trials, s how they are
conducted, and the costs of such trials.' 9 Next, an analysis of the current law
relating to insurance coverage of cancer clinical trials is presented. 0 Finally, this
Note discusses the mandates of Chapter 172 and its likely effect on insurance
coverage of cancer clinical trials.'

9. See id. at 707; infra Part ll.A (describing the different stages of clinical trials).
10. Harris, 992 F.2d at 710.
11. Id.
12. Infra Part I.A.
13. Harris,992 F.2d at 710.
14. See Dozsa v. Crum & Forster Ins. Co., 716 F. Supp. 131, 135 (D.N.J. 1989) (quoting David W.
Plocher, M.D., the Vice President of Medical Services at Prudential, when asked how Prudential determines if a
novel treatment is covered); Letter from Nancy Davenport-Ennis, CEO, National Patient Advocate Foundation,
to the Health Care Financing Administration (July 17, 2000) [hereinafter Davenport-Ennis Letter] (on file with
the McGeorge Law Review) (stating that reimbursement of new therapies aided the progress of the treatment of
pediatric cancer over many decades).
15. See Nancy A. Wynstra, Breast Cancer: Selected Legal Issues, 74 CANCER 491 (1994) (explaining
the "hotly contested" legal issue of reimbursement of unproven treatments, such as clinical trials).
16. See Harris, 992 F.2d at 711 (stating that Ms. Harris' suit against her insurance failed). Under the
Administrative Procedures Act 5 U.S.C.A. § 706(2)(a), the Office of Personnel Management's (OPM)
determination was final, unless the decision was "arbitrary and capricious." Therefore, whether or not the
clinical trial was experimental or standard medical practice was not at issue. Id.
17. Wynstra, supra note 15, at 491-92 (noting that society and health plans each have an interest in not
paying for unproven treatments because it is not cost effective).
18. See infra Part lI.A-C (noting the structure and costs of clinical trials).
19. Infra Part H.A-C.
20. See infra Part III (discussing the existing law).
21. See infra Part V (analyzing the possible effects of Chapter 172).
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II. BACKGROUND

A. Clinical Trials
Prescription drugs go through a more rigorous process than medical devices,
while medical procedures are not put through the regulatory process at all.22 For
instance, a new drug may not be marketed unless the Food and Drug
Administration (FDA) approves it as safe and effective.23 Clinical trials are
another prerequisite for determination of safety and effectiveness.
Organizations or individuals marketing a drug, device, or product sponsor
clinical trials, and it is the sponsor who must ensure that the trial is conducted
both legally and ethically. 2 Each clinical trial is based on a set of rules called a
protocol. 26 A protocol sets forth who may participate in the trial and determines
the appropriate procedures, medications, and dosages to be used in the clinical
trials. 27 All protocols must be approved by the sponsor of the study and by the
8
Institutional Review Board (IRB) at the facility where the trial is conducted.
There are IRB groups at every facility conducting clinical trials.29 IRBs are
groups of doctors, clergy members, and consumers who review protocols to
ensure patient safety.30 In fact, IRBs must review and approve protocols for all
clinical trials funded by the federal government.3
Clinical trials are conducted in four phases. Phase I studies are almost
exclusively conducted at specialized research centers which evaluate a
treatment's safety and typically involve twenty to eighty patients.32 In Phase II
studies, the new treatment is generally administered to a larger group of people,
between one hundred to three hundred, to further evaluate its safety.33 Phase III
studies are typically conducted on an even larger group of people, between one to
three thousand. This phase monitors side effects, compares the new treatment to
currently used treatments, and collects more data on its safety.33 To compare data

22. Harness, supra note 2, at 70.
23. 21 U.S.C.A § 355(a) (West 1999).
24. Id. § 355(d) (giving guidelines for approval, specifically requiring "substantial evidence").
25. See National Institute of Health, What is a Clinical Trial? (July 22, 2001), at http://www.clinical
trials.gov (giving a detailed description of the structure of clinical trials).
26. Id.
27. Id.
28. See Taking Part in Clinical Trials: What Cancer Patients Need to Know, CancerNet (Nat'l Cancer
Inst., Bethesda, Md.), revised May 1998 at 1, 3-4, http://cancernet.nci.nih.gov/peb/taking-part-treatment/
index.html [hereinafter Taking Part](discussing IRBs and structure of clinical trials).
29. Id.
30. Id. at 10.
31. National Institute of Health, supra note 25, at 5.
32. Id. at 2.
33. Id.
34. Id.
35. Id.
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between Phase II and Phase III trials, participants in Phase III trials are randomly
assigned to receive either the new treatment or the standard treatment, to avoid
any bias in the study.36 In fact, some studies do not inform patients whether or not
they are in the control group.37 Finally, Phase IV studies consist of continued
investigations after the drug, treatment, or procedure is marketed, to determine
the effects on various populations including long-term side effects.38
B. Costs of Clinical Trials
There are two types of costs associated with clinical trials: patient care and
research costs.3 9 Patient care costs include items such as doctor visits, x-rays, and
hospital stays.40 Research costs include the costs associated with data collection.4'
One study compared costs of 135 patients in 22 Phase II cancer clinical trials,
to 135 matched control subjects.42 This research found that the clinical trial
enrollees, on average, had a higher one-year medical care cost. 43 The increase is
largely due to costs associated with receiving Bone Marrow Transplant (BMT),
as the costs of patients participating without BMT were no higher than those in
the control group."
C. Participationin ClinicalTrials
Less than four percent of adults with cancer are enrolled in clinical trials.43
One reason for low participation in clinical trials is a lack of consistency in
insurance coverage.46 Some scholars argue that covering costs of clinical trials is
the "first step" in increasing participation in cancer clinical trials.47

36. Taking Part, supra note 28, at 5.
37. See id. (defining a control group as those patients receiving the "standard treatment" rather than the
new treatment).
38. ld. at 2.
39. ASSEMBLY COMMITTEE ON HEALTH, COMMITTEE ANALYSIS OF SB 37, at 7-8 (June 19, 2001).
40. Id.
41. Id.
42. See Bruce H. Fireman et al., Cost of Carefor Patients in Cancer Clinical Trials, 92 J. NAT'L
CANCER INST. 136, 136 (Jan. 19, 2000) (defining matched control subjects as "comparison subjects").
43. See id. at 142 (stating that enrollees had higher one-year costs by $1,487, or about ten percent).
44. Id.
45.

ASSEMBLY COMMITTEE ON HEALTH, COMMITTEE ANALYSIS OF SB 37, at 6 (June 19, 2001); Letter

from Arlyne Draper, President/Co-Founder, California Breast Cancer Organizations, to Jackie Speier, Senator
(Feb. 14, 2001) (on file with the McGeorge Law Review).
46. Harness, supra note 2, at 71.
47. Draper, supra note 45.
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III.

EXISTING LAW

Existing California law requires health insurance plans to provide only "basic
health care services. ',48 Provided those basic services are included, an insurance
policy contract can include or exclude any other types of benefits.
Contract language therefore controls whether a treatment is covered by the
health insurance plan.49 When a person is denied treatment that is specifically
excluded from the policy, the policyholder has no contractual remedy available. 5 o
Courts only review the contract provisions to which both parties agreed.5 When
examining a contract, the denial of benefits is never addressed; rather, only the
contract language is reviewed. 52
Case law on the denial of coverage for clinical trials as experimental is
remarkably inconsistent. 3 To complicate the matter further, one insurance carrier
may cover clinical trials while another may not. 4 This inconsistency reveals that
there is no universal definition of what constitutes experimental treatment in
either the legal or in the health care industry.55
IV. CHAPTER 172

Chapter 172 requires health service plans, disability insurers, and Medi-Cal
to provide coverage for all "routine patient care costs" associated with clinical
trials, for patients who are diagnosed with cancer and accepted into a Phase I, II,

48. See

ASSEMBLY COMMITrEE ON HEALTH, COMMIrTEE ANALYSIS OF

SB 37, at 4 (June 19, 2001)

(giving examples of basic services: physician, hospital, diagnostic, home health, preventative, emergency, and
hospice care).
49. See Thomas v. Gulf Health Plan, Inc., 688 F. Supp. 590, 595 (S.D. Ala. 1988) (stating that a court
must uphold the plan administrator's decision regarding the contract unless a court determines that it was
"arbitrary and capricious"); Bechtold v. Physicians Health Plan, 19 F.3d 322, 327 (7th Cir. 1994) (asserting that
courts can only interpret language of the insurance contract in question).
50. Smayda, supra note 7, at 266.
51. Id.
52. Id. at 267.
53. See, e.g., DiDomenico v. Employers Coop. Indus. Trust, 676 F. Supp. 903, 907-08 (N.D. Ind. 1987)
(ordering treatment because the contract was not clear as to whether the liver transplant procedure or the
patient's age made the treatment experimental); Adams v. Blue Cross/Blue Shield, 757 F. Supp. 661, 666
(D. Md. 1991) (deeming a treatment experimental if the treatment was not the accepted practice in the area);
Fassio v. Mont. Physicians' Serv., 553 P.2d 998, 1002 (Mont. 1976) (ordering payment for treatment of
Mongolism because the denial was based on an exclusion that was a change in policy and because the
beneficiaries did not receive notice of the change); Jacob v. Blue Cross/Blue Shield, P.2d 382, 384 (Or. 1988)
(holding there is no ambiguity in the exclusionary provision of an "experimental procedure"); Harris v. Mut. of
Omaha 992 F.2d 706, 707-08 (7th Cir. 1993) (holding contract language specifically excluded experimental
treatment, including clinical trials, unless efficacy was proven with reliable evidence as determined by the
Plan).
54. William B. Farrar, ClinicalTrials: Access and Reimbursement, 67 CANCER 1779, 1781 (1991).
55. Richard S. Saver, Reimbursing New Technologies: Why Are the Courts Judging Experimental
Medicine?, 44 STAN. L. REV. 1095, 1098 (1992).
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III, or IV clinical trial. 6 "Routine patient care costs" are services that would
normally be covered by the plan if treatment was not part of a clinical trial.57
Services for reasonable and necessary care for an investigational treatment and
any complications arising from the investigational treatment are also included. 8
The patient's normal co-payments and deductibles will apply to services rendered
in the clinical trial.59 Specifically excluded from "routine patient care costs" are
drugs or devices not approved by the FDA, although part of the clinical trial;
travel expenses; pure data collection services; services normally performed at no
charge; and services specifically excluded under the policy. 60
A condition of coverage of the clinical trial is that the treating physician,
providing services under the enrollee's health plan, must determine that the
clinical trial has "meaningful potential" to benefit the patient before
recommending participation in the clinical trial.6 Interestingly, the statute does
not define• "meaningful
potential" or provide any specific criteria for meeting this
61
requirement.
V. EFFECTS OF CHAPTER 172

Currently, the level of participation in cancer clinical trials is extremely
low. 61 Increased participation is needed because clinical trials refine new

treatments into the most efficacious treatment possible.6" However, improvements
56. See CAL. HEALTH & SAFETY CODE § 1370.6(a) (enacted by Chapter 172) (requiring managed care
organizations to cover cancer clinical trials); CAL. INS. CODE § 10145.4(a) (enacted by Chapter 172) (requiring
all disability insurances including indemnity plans and preferred provider organizations, to cover cancer clinical
trials); CAL. WELF. & INST. CODE § 14087.11 (b) (enacted by Chapter 172) (requiring County Organized Health
System contracts to cover cancer clinical trials). This program is similar to the state Medi-Cal program but is
administered at the county level. Id.; CAL. WELF. & INST. CODE § 14132.98(a) (enacted by Chapter 172)
(requiring Medi-Cal to cover cancer clinical trials).
57. CAL. HEALTH & SAFETY CODE § 1370.6(b)(1) (enacted by Chapter 172); CAL. INS. CODE
§ 10145.4(b)(1) (enacted by Chapter 172); CAL. WELF. & INST. CODE § 14087.11 (c)(1) (enacted by Chapter
172); CAL WELF. & INST. CODE § 14132.98(b)(1) (enacted by Chapter 172).
58. CAL. HEALTH & SAFETY CODE §§ 1370.6(b)(1)(B)-(E) (enacted by Chapter 172); CAL INS. CODE
§§ 10145.4(b)(1)(B)-(E) (enacted by Chapter 172); CAL. WELF. & INST. CODE §§ 14087.11(c)(1)(B)-(E)
(enacted by Chapter 172).
59. CAL. HEALTH & SAFETY CODE § 1370.6(i) (enacted by Chapter 172); CAL. INS. CODE § 10145.4(i)
(enacted by Chapter 172); CAL. WELF. & INST. CODE §§ 14087.1 1(c)(l)(B)-(C) (enacted by Chapter 172).
60. CAL. HEALTH & SAFETY CODE §§ 1370.6(b)(2)(A)-(E) (enacted by Chapter 172); CAL. INS. CODE
§§ 10145.4(b)(2)(A)-(E) (enacted by Chapter 172); CAL. WELF. & INST. CODE §§ 14087.11(c)(2)(A)-(E)
(enacted by Chapter 172); CAL. WELF. & INST. CODE §§ 14132.98(b)(2)(A)-(E) (enacted by Chapter 172).
61. CAL. HEALTH & SAFETY CODE § 1370.6(a) (enacted by Chapter 172); CAL. INS. CODE § 10145.4(a)
(enacted by Chapter 172); CAL. WELF. & INST. CODE § 14087.11 (b) (enacted by Chapter 172); CAL. WELF. &
INST. CODE § 14132.98(a) (enacted by Chapter 172).
62. CAL. HEALTH & SAFETY CODE § 1370.6(a) (enacted by Chapter 172); CAL. INS. CODE § 10145.4(a)
(enacted by Chapter 172); CAL. WELF. & INST. CODE § 14087.1 1(b) (enacted by Chapter 172); CAL. WELF. &
INST. CODE § 14132.98(a) (enacted by Chapter 172).
63. See supra Part II.C (discussing clinical trial participation).
64. See Letter from Theresa M. Renken, Legislative Advocate, American Cancer Society, to Sam
Aanestad, Assemblymember (July 12, 2001) (on file with the McGeorge Law Review) (stating that increased
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in treatment usually occur very slowly.65 Therefore, it follows that, if more health
insurance plans cover costs associated with cancer clinical trials, more people
with cancer will participate in clinical trials, resulting in an increase in the rate of
cancer treatment improvements. The drafters of Chapter 172 have such a hope. 66
Proponents of Chapter 172 justify broad mandatory coverage of clinical trials
by relying on research that indicates the costs of treating people in a clinical trial
are not significantly greater than the costs of treating people not enrolled in the
clinical trials.6 However, the statistics used are misleading because the study
analyzed data from clinical trials that were not a "representative sample" of all
cancer clinical trials.6" Rather, the study was exclusively based on clinical trials
performed at Kaiser Permanente.6 ' The authors of that study concede that costs of
clinical trials vary with the type of treatment being evaluated. 70 Thus, the
financial impact on health plans remains uncertain.
For instance, Chapter 172 requires coverage for all stages of clinical trials. 71
Before the adoption of Chapter 172, Medi-Cal typically covered Phase III and
IV, but not Phase I and 11.72 The Assembly Appropriations Committee estimates73
costs to the Medi-Cal program will increase approximately $300,000 annually.
Rising costs will not be exclusive to Medi-Cal. Any health insurance plan that
does not cover routine costs associated with clinical trials, which Chapter 172
now requires, will incur new costs. 7' This increase in costs could reasonably be
passed down to enrollees in the form of increased premium prices. 7' The increase

enrollment helps make treatments available); Draper, supra note 45 (indicating that clinical trials are necessary
to learn how to effectively treat illnesses like cancer).
65. See Davenport-Ennis Letter, supra note 14 (on file with the McGeorge Law Review) (explaining that
progress in the treatment of pediatric cancer came from decades of "incremental improvements").
66. ASSEMBLY COMMITTEE ON HEALTH, COMMITTEE ANALYSIS OF SB 37, at 6 (June 19, 2001) (stating
the purpose of the Bill is to increase participation in cancer clinical trials in hope of finding cures for various
cancers).
67. See supra Part I.B (comparing the costs of treating patients in clinical trials with the costs of
treating patients receiving standard treatment).
68. See Cary A. Presant, Correspondence: PatientCosts on Clinical Trials, 92 J. NAT'L CANCER INST.
1441, 1442 (Sept. 6, 2000) (summarizing a response to Presant by Bruce Fireman, Louis Fehrenbacher, and G.
Thomas Ray).
69. Id.
70. Id.
71. See supra Part IV (detailing what CHAPTER 172 covers); CAL. HEALTH & SAFETY CODE § 1370.6(a)
(enacted by Chapter 172); CAL. INS. CODE § 10145.4(a) (enacted by Chapter 172); CAL. WELF. & INST. CODE
§ 14087.11 (b) (enacted by Chapter 172); CAL. WELF. & INST. CODE § 14132.98(a) (enacted by Chapter 172).
72. ASSEMBLY COMMITTEE ON APPROPRIATIONS, COMMITTEE ANALYSIS OF SB 37, at 2 (July 11, 2001).
73. See id. (stating that there are currently fifteen thousand people participating in Phase I and II clinical
trials in California). If Chapter 172 increases participation in those phases by ten percent, the estimated number
of Medi-Cal participants would be approximately two hundred. This figure multiplied by the average cost
increase of $1,487 per person will increase total costs to the program by approximately $297,400. Id.
74. See ASSEMBLY COMMITTEE ON HEALTH, COMMITTEE ANALYSIS OF SB 37, at 6 (June 19, 2001)
(noting that early opposition to SB 37 warned that mandating coverage of clinical trials would increase health
insurance premiums and possibly the number of those uninsured).
75. Id.
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in premiums could put health coverage out of reach for some, thereby raising the
16
number of California's uninsured patients.
Additional concerns exist about the effectiveness of Chapter 172 in
increasing participation in clinical trials and health plans paying for the
corresponding routine costs. Chapter 172 explicitly defines what is considered
routine costs and what is not." However, Chapter 172 does not define the phrases
"meaningful potential" or "reasonable and necessary."78
Ambiguous language such as "reasonable and necessary" is precisely what
gave rise to inconsistent coverage of clinical trials (allowing companies to
include clinical trials as an investigational or experimental treatment), and such
ambiguous language is the obstacle this legislation is designed to remedy.7 One
clue as to how "meaningful potential" and "reasonable and necessary" might be
interpreted is to analogize to the proposed Medicare standard of review for access
to new technologies. 0 The proposed Medicare rule provides criteria for
determining "reasonable and necessary."8 ' For instance, "breakthrough
technology" and treatments that are "medically beneficial" are criteria that have
been proposed.82 The Health Care Financing Administration stated that the
Medicare standard of "medically beneficial" is met when objective scientific
evidence establishes that the new procedure will produce a better outcome than if
the patient 3received no treatment or the customary medical management of
8
symptoms.
The proposed standard by Medicare will likely not help increase participation
in clinical trials because most progress in the treatment of cancer is attributable to
small refinements in treatment over many years, rather than "breakthroughs" in
treatments.8 Therefore, if the "meaningful potential" or "reasonable and
necessary" conditions of Chapter 172 are interpreted as a standard similar to
Medicare's proposed rules, Chapter 172 may actually fall short of its purposepromoting clinical trials to help find a cure for cancer.

76. Id.
77. See supra Part IV (defining "routine patient care costs").
78. See supra Part IV (discussing "meaningful potential" and "reasonable and necessary").
79. See supra Part III (detailing inconsistent judicial treatment of ambiguous contract language, such as
the term "medical necessity").
80. Proposed Medicare Program Rules from Department of Health and Human Services and Health Care
Financing Administration, 65 Fed. Reg. 31,124 (proposed May 16, 2000) (to be codified at 42 C.F.R. pt. 405).
81. Id.at3l,126.
82. Id. at 31,125.
83. See Davenport-Ennis Letter, supra note 14 (commenting on the Medicare standard).
84. Proposed Medicare Program Rules from Department of Health and Human Services and Health Care
Financing Administration, 2 Fed. Reg. 31,125 (proposed May 16, 2000) (to be codified at 42 C.F.R. pt. 405).
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VI. CONCLUSION

Chapter 172 attempts to increase participation in cancer clinical trials by
mandating that health plans cover routine costs associated with cancer clinical
trials which, in turn, will improve treatment and ultimately help find a cure for
cancer.85 It is not clear whether Chapter 172 will actually increase clinical trial
participation. Quarrels over ambiguity in the statute's language may continue to
exclude candidates from participation. 16 At the very least, Chapter 172 will give
people like Ms. Harris some assurance that their health insurance plans are now
more likely to cover cancer clinical trials."87

85.

ASSEMBLY COMMIrrEE ON HEALTH, COMMITTEE ANALYSIS OF SB 37, at 6 (June 19, 2001)

(summarizing the purpose of the Bill as increasing participation in cancer clinical trials to find a cure for
cancer).
86. See supra Part IV (discussing previous problems with ambiguous language such as "reasonable and
necessary").
87. See supra Part I (discussing the problems Ms. Harris encountered when trying to persuade her
insurance carrier to cover the costs of her participation in a cancer clinical trial).

